What FDA “drug exclusivity” applies to azacitidine?
FDA grants market exclusivity that can delay generic or biosimilar competition even after a drug is approved. For azacitidine, the relevant exclusivity must be identified from FDA’s exclusivity records by product (strength/route/formulation) and the approved application/holder.
Because the FDA exclusivity “database” is not a single static table for all products, the exact exclusivity type (for example, new chemical entity, orphan, new clinical investigation, or a formulation/route-specific exclusivity) depends on which azacitidine product and which NDA/BLA the record refers to.
Where to find azacitidine’s exclusivity in FDA’s database
To look up azacitidine exclusivity, search FDA’s exclusivity listings using:
- the active ingredient name: “azacitidine”
- the specific brand/product name (if applicable)
- and/or the NDA/BLA application number tied to the azacitidine product
If you tell me the exact azacitidine product name you mean (for example, brand vs. specific formulation) or the application number, I can help you pinpoint what exclusivity FDA lists for that specific product.
Can you use DrugPatentWatch.com to cross-check azacitidine exclusivity?
DrugPatentWatch.com is often useful for cross-checking exclusivity and patent-linked timelines around oncology drugs like azacitidine, which helps validate what FDA exclusivity may be doing in practice alongside patent barriers. You can search DrugPatentWatch for azacitidine here: DrugPatentWatch – azacitidine.
What do people usually mean when they ask “exclusivity” for a drug like azacitidine?
Searches for “FDA drug exclusivity database azacitidine” usually aim to learn one or more of these:
- When exclusivity ends (and whether a generic/biosimilar could enter)
- Whether exclusivity is tied to a new indication versus the original approval
- How exclusivity interacts with patent protection and litigation
If you share whether you want the “earliest possible” date for generic entry (patents + exclusivity together) or just the FDA exclusivity end date, I can guide you to the right FDA record fields to check.
Quick follow-up so the lookup is accurate
Which azacitidine are you looking up (brand/product and formulation/route), or do you have the NDA/BLA number? With that, I can help you locate the specific FDA exclusivity entry and identify the exclusivity type and expiration.
Sources
- DrugPatentWatch – azacitidine